Sadayappan Laboratory

Laboratory of

Sakthivel Sadayappan

As our long-term goal, we aim to delineate the role of myosin binding protein- C (MyBP- C) structure, regulation, and function in striated muscles of both cardiac and skeletal tissues in health and diseases. We are committed to exploring the regulation of MyBP-C in various preclinical and clinical conditions using in vitro, ex vivo, and in vivo approaches.

Our research is driven by the desire to improve cardiac health with the long-term goal of treating and preventing the development of genetically induced heart failure, such as hypertrophic cardiomyopathy, congenital heart disease, and dilated cardiomyopathy. In the last five years, we have expanded our portfolio to define skeletal muscle genetic diseases, such as distal arthrogryposis and Lethal Congenital Contracture Syndrome. Our team has focused on studying the regulation of cardiac, skeletal, and smooth muscles in health and various pathophysiological conditions. Specifically, our studies include iPSC-derived cardiomyocytes, iPSC-derived cardiac organoids, genetically engineered mouse models, and gene corrections using CRISPR-mediated gene therapy, AAV-mediated gene therapy, and antisense oligonucleotides. We work directly with various pharmaceutical companies to perform translational preclinical and clinical trials. Some ongoing studies aim to develop small-molecule and peptide therapies to treat heart failure.

Lab Members